219 related articles for article (PubMed ID: 16584149)
1. Formulation of a dry powder influenza vaccine for nasal delivery.
Garmise RJ; Mar K; Crowder TM; Hwang CR; Ferriter M; Huang J; Mikszta JA; Sullivan VJ; Hickey AJ
AAPS PharmSciTech; 2006 Mar; 7(1):E19. PubMed ID: 16584149
[TBL] [Abstract][Full Text] [Related]
2. Formulation of a dry powder influenza vaccine for nasal delivery.
Garmise RJ; Mar K; Crowder TM; Hwang CR; Ferriter M; Huang J; Mikszta JA; Sullivan VJ; Hickey AJ
AAPS PharmSciTech; 2006 Mar; 7(1):E131-E137. PubMed ID: 28290034
[TBL] [Abstract][Full Text] [Related]
3. Dry Formulations Enhanced Mucoadhesive Properties and Reduced Cold Chain Handing of Influenza Vaccines.
Saengkrit N; Saesoo S; Woramongkolchai N; Sajomsang W; Phunpee S; Dharakul T; Ruktanonchai UR
AAPS PharmSciTech; 2018 Nov; 19(8):3763-3769. PubMed ID: 30259401
[TBL] [Abstract][Full Text] [Related]
4. Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration.
Sou T; Morton DA; Williamson M; Meeusen EN; Kaminskas LM; McIntosh MP
J Aerosol Med Pulm Drug Deliv; 2015 Oct; 28(5):361-71. PubMed ID: 25714115
[TBL] [Abstract][Full Text] [Related]
5. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination.
Garmise RJ; Staats HF; Hickey AJ
AAPS PharmSciTech; 2007 Oct; 8(4):E81. PubMed ID: 18181542
[TBL] [Abstract][Full Text] [Related]
6. Physical and immunogenic stability of spray freeze-dried influenza vaccine powder for pulmonary delivery: comparison of inulin, dextran, or a mixture of dextran and trehalose as protectants.
Murugappan S; Patil HP; Kanojia G; ter Veer W; Meijerhof T; Frijlink HW; Huckriede A; Hinrichs WL
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):716-25. PubMed ID: 23933147
[TBL] [Abstract][Full Text] [Related]
7. Toward intradermal vaccination: preparation of powder formulations by collapse freeze-drying.
Etzl EE; Winter G; Engert J
Pharm Dev Technol; 2014 Mar; 19(2):213-22. PubMed ID: 23432539
[TBL] [Abstract][Full Text] [Related]
8. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation.
Maa YF; Ameri M; Shu C; Payne LG; Chen D
J Pharm Sci; 2004 Jul; 93(7):1912-23. PubMed ID: 15176078
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of intranasal delivery of thin-film freeze-dried, mucoadhesive vaccine powders.
Yu YS; AboulFotouh K; Xu H; Williams G; Suman J; Cano C; Warnken ZN; Wu KC; Williams RO; Cui Z
Int J Pharm; 2023 Jun; 640():122990. PubMed ID: 37127138
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to the pulmonary delivery of liposomes in dry powder form to eliminate the deleterious effects of milling.
Desai TR; Wong JP; Hancock RE; Finlay WH
J Pharm Sci; 2002 Feb; 91(2):482-91. PubMed ID: 11835207
[TBL] [Abstract][Full Text] [Related]
11. Stability of collapse lyophilized influenza vaccine formulations.
Anamur C; Winter G; Engert J
Int J Pharm; 2015 Apr; 483(1-2):131-41. PubMed ID: 25660049
[TBL] [Abstract][Full Text] [Related]
12. Liposomal dry powders as aerosols for pulmonary delivery of proteins.
Lu D; Hickey AJ
AAPS PharmSciTech; 2005 Dec; 6(4):E641-8. PubMed ID: 16408866
[TBL] [Abstract][Full Text] [Related]
13. Spray-freeze-drying for protein powder preparation: particle characterization and a case study with trypsinogen stability.
Sonner C; Maa YF; Lee G
J Pharm Sci; 2002 Oct; 91(10):2122-39. PubMed ID: 12226840
[TBL] [Abstract][Full Text] [Related]
14. Formulation of levodopa containing dry powder for nasal delivery applying the quality-by-design approach.
Bartos C; Pallagi E; Szabó-Révész P; Ambrus R; Katona G; Kiss T; Rahimi M; Csóka I
Eur J Pharm Sci; 2018 Oct; 123():475-483. PubMed ID: 30076956
[TBL] [Abstract][Full Text] [Related]
15. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
16. Developments in the formulation and delivery of spray dried vaccines.
Kanojia G; Have RT; Soema PC; Frijlink H; Amorij JP; Kersten G
Hum Vaccin Immunother; 2017 Oct; 13(10):2364-2378. PubMed ID: 28925794
[TBL] [Abstract][Full Text] [Related]
17. Effect of milling and sieving on functionality of dry powder inhalation products.
Steckel H; Markefka P; teWierik H; Kammelar R
Int J Pharm; 2006 Feb; 309(1-2):51-9. PubMed ID: 16377105
[TBL] [Abstract][Full Text] [Related]
18. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery.
Alhalaweh A; Andersson S; Velaga SP
Eur J Pharm Sci; 2009 Oct; 38(3):206-14. PubMed ID: 19616094
[TBL] [Abstract][Full Text] [Related]
19. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
Dehghan S; Tafaghodi M; Bolourieh T; Mazaheri V; Torabi A; Abnous K; Tavassoti Kheiri M
Int J Pharm; 2014 Nov; 475(1-2):1-8. PubMed ID: 25148732
[TBL] [Abstract][Full Text] [Related]
20. Following mechanical activation of salbutamol sulphate during ball-milling with isothermal calorimetry.
Gaisford S; Dennison M; Tawfik M; Jones MD
Int J Pharm; 2010 Jun; 393(1-2):74-8. PubMed ID: 20385222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
